Literature DB >> 18456377

Immunodeficiency-associated lymphomas.

Huy Tran1, Jamie Nourse, Sara Hall, Michael Green, Lyn Griffiths, Maher K Gandhi.   

Abstract

This article covers lymphoproliferative disorders in patients with primary or acquired immunodeficiencies. Primary immunodeficiences include Ataxia Telangiectasia and X-linked disorders such as Wiskott-Aldrich syndrome. Acquired immunodeficiencies predominantly occur in the setting of infection with the Human Immunodeficiency Virus or arise following immunosuppressive therapy administered after organ transplantation. The rising incidence of HIV throughout the world and the dramatic increase in transplant surgery since the 1990's suggest that these lymphomas will remain an important health problem. Evidence for lymphoma developing as a result of treatment with methotrexate or Tumour Necrosis Factor Antagonists for autoimmune entities will also be reviewed. The lymphoproliferations that occur with immunodeficiency are extremely heterogenous. In part this reflects the diversity of the causal immune defect. The most striking clinical characteristic is the high frequency of extranodal disease. Frequently, these lymphomas are driven by viruses such as Epstein-Barr virus (EBV), although the lack of EBV in a proportion indicates that alternate pathways must also be involved in the pathogenesis. Lastly, discussion will centre on mechanisms utilized by lymphomas in the immunodeficient as these may have applications to lymphomas in the "immunocompetent", by serving as a paradigm for the altered immunoregulatory environment present in many lymphoma sub-types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456377     DOI: 10.1016/j.blre.2008.03.009

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  37 in total

Review 1.  2,4-dichlorophenoxyacetic acid (2,4-D) and risk of non-Hodgkin lymphoma: a meta-analysis accounting for exposure levels.

Authors:  Adam M Smith; Martyn T Smith; Michele A La Merrill; Jane Liaw; Craig Steinmaus
Journal:  Ann Epidemiol       Date:  2017-03-31       Impact factor: 3.797

2.  B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency.

Authors:  Hannelore I Bax; Alexandra F Freeman; Victoria L Anderson; Per Vesterhus; Dan Laerum; Stefania Pittaluga; Wyndham H Wilson; Steven M Holland
Journal:  J Clin Immunol       Date:  2013-06-26       Impact factor: 8.317

3.  Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.

Authors:  Hikmet G Tanyildiz; Handan Dincaslan; Gulsan Yavuz; Emel Unal; Aydan Ikinciogulları; Figen Dogu; Nurdan Tacyildiz
Journal:  J Clin Immunol       Date:  2016-08-04       Impact factor: 8.317

4.  Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.

Authors:  Sally A Mujaj; Michelle M Spanevello; Maher K Gandhi; Jamie P Nourse
Journal:  Am J Blood Res       Date:  2011-05-22

5.  Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes.

Authors:  Do Nguyen-Van; Colm Keane; Erica Han; Kimberley Jones; Jamie P Nourse; Frank Vari; Nathan Ross; Pauline Crooks; Olivier Ramuz; Michael Green; Lyn Griffith; Ralf Trappe; Andrew Grigg; Peter Mollee; Maher K Gandhi
Journal:  Am J Blood Res       Date:  2011-09-09

6.  Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.

Authors:  Leon D Kaulen; Daniela Galluzzo; Pei Hui; Frank Barbiero; Philipp Karschnia; Anita Huttner; Robert Fulbright; Joachim M Baehring
Journal:  J Neurooncol       Date:  2019-06-13       Impact factor: 4.130

7.  A possible familial lymphoproliferative disorder in two male siblings of children with recurrent wheezing and lung infections since infancy.

Authors:  Shih-Hsiang Chen; Shao-Hsuan Hsia; Jainn-Jim Lin; Kin-Sun Wong; Chih-Wei Wang; Lee-Yung Shih; Wen-I Lee
Journal:  Int J Hematol       Date:  2014-06-17       Impact factor: 2.490

8.  Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive.

Authors:  Emily McKeown; Janet E Pope; Suzanne Leaf
Journal:  Open Rheumatol J       Date:  2009-07-13

9.  A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.

Authors:  Michael R Green; Paul Jardine; Peter Wood; Jeremy Wellwood; Rod A Lea; Paula Marlton; Lyn R Griffiths
Journal:  BMC Cancer       Date:  2010-05-12       Impact factor: 4.430

10.  Immune surveillance and lymphoid malignancy in immunocompromised host.

Authors:  Patrick L Stevens; Nishitha M Reddy
Journal:  Am J Blood Res       Date:  2013-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.